Type 2 immunity: a two-edged sword in schistosomiasis immunopathology.
Trends Immunol
; 43(8): 657-673, 2022 08.
Article
en En
| MEDLINE
| ID: mdl-35835714
ABSTRACT
Schistosomiasis is the second most debilitating neglected tropical disease globally after malaria, with no available therapy to control disease-driven immunopathology. Although schistosomiasis induces a markedly heterogenous immune response, type 2 immunity is the dominating immune response following oviposition. While type 2 immunity has a crucial role in granuloma formation and host survival during the acute stage of disease, its chronic activation can result in tissue scarring, fibrosis, and organ impairment. Here, we discuss recent advances in schistosomiasis, demonstrating how different immune and non-immune cells and signaling pathways are involved in the induction, maintenance, and regulation of type 2 immunity. A better understanding of these immune responses during schistosomiasis is essential to inform the potential development of candidate therapeutic strategies that fine-tune type 2 immunity to ideally modulate schistosomiasis immunopathology.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Esquistosomiasis
Límite:
Female
/
Humans
Idioma:
En
Revista:
Trends Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2022
Tipo del documento:
Article